<DOC>
	<DOCNO>NCT01923363</DOCNO>
	<brief_summary>Worldwide rate obesity double last 30 year , obesity associate risk factor hospital-acquired infection increase occurrence death critically-ill patient . Piperacillin/tazobactam commonly prescribe antibiotic critically ill patient infection , however , limited information exist dose drug obese patient . In limited report , standard dos piperacillin/tazobactam give small number obese patient result low blood concentration , could lead inadequate kill bacteria . The purpose study compare blood concentration standard piperacillin/tazobactam dosing compare higher dose regimen obese patient . This study also include information safety tolerability high dose regimen . The study investigator believe high dose regimen produce adequate blood level obese patient add risk harm obese patient receive high dose .</brief_summary>
	<brief_title>PK/PD High Dose Pip/Tazo Obese Patients</brief_title>
	<detailed_description />
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<criteria>BMI great equal 30 kg/m2 Weight least 105 kg Age 1889 year age Prescribed piperacillin/tazobactam standard dos suspect confirmed infection ( ) English Spanish speak Central line access Do meet specified inclusion criterion Hepatic impairment classify ChildPugh Class B great Documented preexisting seizure disorder Documented preexist hematologic disorder Pregnancy Documented allergy contraindication betalactams tazobactam</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>obesity</keyword>
	<keyword>piperacillin-tazobactam combination product</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>piperacillin/tazobactam</keyword>
</DOC>